Masimo (NASDAQ:MASI) Issues Q3 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its third quarter earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.81-0.86 for the period, compared to the consensus estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.48 million. Masimo also updated its Q3 2024 guidance to 0.810-0.860 EPS.

Masimo Price Performance

NASDAQ:MASI opened at $133.77 on Thursday. The company has a market cap of $7.11 billion, a P/E ratio of 91.00 and a beta of 0.98. The firm’s fifty day moving average price is $116.15 and its two-hundred day moving average price is $124.92. Masimo has a one year low of $75.22 and a one year high of $153.93. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.09. The firm had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The business’s revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 EPS. Equities analysts expect that Masimo will post 3.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MASI shares. Piper Sandler boosted their price target on Masimo from $160.00 to $165.00 and gave the company an overweight rating in a research note on Wednesday, August 7th. Needham & Company LLC reissued a hold rating on shares of Masimo in a research report on Friday, September 20th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $144.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.